AlphaLISA® Acceptor beads conjugated to anti-human IgG1. These beads can be used in conjunction with Alpha Donor beads to create AlphaLISA no-wash assays for antibody binding studies, pharmacokinetics (PK), or detection of human IgG1 in different sample matrices, including monkey serum.
Please enter valid quantity
Please login to add favorites
NULL OR EMPTY CART
|Part Number||Unit Size||List Price||Your Price||Quantity|
|AL141C||250 µg||553.00 USD|
|AL141M||5 mg||5500.00 USD|
|AL141R||25 mg||22700.00 USD|
You successfully added item(s) to your cart
An AlphaLISA assay using these Acceptor beads allows the detection of human IgG1 in buffer, cell culture media, serum and plasma in a highly sensitive, quantitative, reproducible and user-friendly mode. These beads (along with a suitable Donor bead) permit antibody binding studies or detection of human IgG1 in different sample matrices, including monkey serum.
In a typical AlphaLISA assay, 1 mg of Acceptor beads is sufficient to run 1,000-2,000 wells using a 50 µL reaction volume.
Immunoglobulin G (IgG), a major effector molecule of the humoral immune response, accounts for about 75% of the total immunoglobulins in plasma of healthy individuals whereas IgM, IgA, IgD and IgE, each of which has characteristic properties and functions, constitute the remaining 25%. The basic IgG molecule has a four-chain structure, comprising two identical heavy (H) chains and two identical light (L) chains, linked together by inter-chain disulfide bonds. Four IgG subclasses have been identified: IgG1, IgG2, IgG3 and IgG4. Biotherapeutic antibody drugs, usually IgG1 or IgG4 molecules, are becoming increasingly important to treat debilitating diseases such as cancer and autoimmune disorders. Drug levels need to be accurately measured at various stages of drug development, including early antibody discovery, preclinical research in animals, and commercial manufacturing.
AlphaScreen® and AlphaLISA® are bead-based assay technologies used to study biomolecular interactions in a microplate format. The acronym ""Alpha"" stands for amplified luminescent proximity homogeneous assay. As the name implies, some of the key features of these technologies are that they are non-radioactive, homogeneous proximity assays. Binding of molecules captured on the beads leads to an energy transfer from one bead to the other, ultimately producing a luminescent/fluorescent signal. To understand how a signal is produced, one must begin with an understanding of the beads. AlphaScreen and AlphaLISA assays require two bead types: Donor beads and Acceptor beads. Each bead type contains a different proprietary mixture of chemicals, which are key elements of the AlphaScreen technology. Donor beads contain a photosensitizer, phthalocyanine, which converts ambient oxygen to an excited and reactive form of O2, singlet oxygen, upon illumination at 680 nm. Please note that singlet oxygen is not a radical; it is molecular oxygen with a single excited electron. Like other excited molecules, singlet oxygen has a limited lifetime prior to falling back to ground state. Within its 4 µsec half-life, singlet oxygen can diffuse approximately 200 nm in solution. If an Acceptor bead is within that proximity, energy is transferred from the singlet oxygen to thioxene derivatives within the Acceptor bead, subsequently culminating in light production at 520-620 nm (AlphaScreen) or at 615 nm (AlphaLISA). In the absence of an Acceptor bead, singlet oxygen falls to ground state and no signal is produced. This proximity-dependent chemical energy transfer is the basis for AlphaScreen's homogeneous nature.
Disclaimer: For research use only. Not for use in diagnostic procedures.
|Antibody Conjugates||Anti-human IgG1|
|Bead Type or Core Bead Type||AlphaLISA Acceptor|
|Experimental Type||In vitro|
|Product Brand Name||AlphaLISA|
|Shipping Condition||Blue Ice|
|Unit Size||5 mg|
You have selected:
|Resource Type||File Name||File Format|
|Brochure||Alpha Technology Solutions||PDF 4 MB|
|Brochure||Alpha product listing||PDF 132 KB|
|Brochure||Handle Large Biomolecular Interactions With Ease||PDF 798 KB|
|Guide||AlphaLISA immunoassay development quick guide||PDF 1 MB|
|Guide||ELISA to AlphaLISA Immunoassay Conversion Guide||PDF 1 MB|
|White Paper||Alpha Technologies for Antibody Detection and Characterization||PDF 534 KB|
|Application Note||A Comparison of AlphaLISA and TR-FRET Homogeneous Immunoassays in Serum-Containing Samples||PDF 1 MB|
|Application Note||Biochemical Binding ADCC Assays Utilizing AlphaLISA Toolbox Reagents||PDF 1 MB|
|Application Note||Development of Pharmacokinetic (PK) Assays for Detecting Biosimilars Targeting TNFa Using AlphaLISA||PDF 2 MB|
|Technical Note||AlphaLISA Ligand Binding Assays for Measurement of Human Immunoglobulin G Subclasses in Animal Sera||PDF 838 KB|
|Poster||All-In-One-Well AlphaLISA Assays for Direct Biomarker Quantification in Cell Cultures||PDF 288 KB|
|Poster||AlphaLISA Assays are Homogeneous Sensitive Immunoassays for Detection of Analytesin a Variety of Biological Matrices||PDF 273 KB|
|Poster||Development of New AlphaLISA No-wash Immunoassay Kits for Sensitive, Rapid and Efficient Quantification of Cytokines||PDF 279 KB|
|Poster||Efficient AlphaLISA immunoassays for the detection and characterization of monoclonal antibody biotherapeutics||PDF 525 KB|
|Flyer||AlphaLISA - Frequently Asked Questions||PDF 102 KB|
|Event||Society of Laboratory Automation & Screening (SLAS)||Event|